SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S. Seasoned Team to Drive Forward Pivotal Phase 3 Trial of Emactuzumab in Patients...

SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1...